Summary Plasma sIl-2R and sCD8 levels of 12 patients with renal cell carcinoma were determined before and during subcutaneous rIl-2 therapy. Patients with a complete/partial remission showed a significantly stronger initial increase of sCD8 compared to patients with stable disease or tumour progression.
Recombinant interleukin-2 (rIl-2) has induced clinical responses in patients with renal cell carcinoma and melanoma (Philip et al., 1986; Rosenberg et al., 1987) . rIl-2 is a glycoprotein (MW = 15,000), normally generated by activated T-(helper) cells and natural killer-(NK)-cells and which has been shown to play an essential role in the activation, differentiation and proliferation of T-cells, B-cells, monocytes and NK-cells. I1-2 acts via membrane-bound receptors on responding cells. The high affinity 11-2 receptor has a double chain molecular structure; the p55 chain (CD25, I1-2-Ralpha) and the p75 chain (Il-2-R-beta). The Il-2-R-beta alone has an intermediate affinity for I1-2 and is operative in signal transduction. In addition to membrane-bound II-2R the existence of a soluble form of the interleukin-2 receptor has been reported which is probably generated by proteolytic cleavage of cell-surface bound p55. These soluble I1-2 receptors (sIl-2R) are produced by activated, but not by resting, T and NK cells (Farrar et al., 1982) and possibly also monocytes (Kniep et al., 1992) .
T suppressor/cytotoxic cells and a subpopulation of NKcells contain a membrane-bound CD8 molecule. CD8 stabilises MHC class I mediated cell-cell interactions, which are involved in for instance MHC restricted T cell cytotoxicity (Fleischer et al., 1986) . During T cell activation CD8-positive cells have been shown to release a soluble form of the CD8 molecule (sCD8) (Tomkinson et al., 1989 ). This ± 30-kDa molecule originates as an alternative splicing product of the CD8-precursor mRNA, in which the exon encoding the transmembrane domain is deleted (Giblin et al., 1989) . The function and possible biological significance of sCD8 is still unclear.
Soluble Il-2R and sCD8 serum concentrations have been used as markers of T cell activation. During the proliferative phase of the immune response in for example the first phase of infection in measles high serum levels of sI12-R were measured. During the effector phase of the induced immune response (during the rash) the sCD8 serum concentration reached a maximum (Griffin et al., 1989) .
In the present study both sIl-2R and sCD8 levels were used as parameters to study the changes in the immune system during subcutaneously administered 11-2 in patients with metastatic renal cell carcinoma.
Materials and methods

Patients
Of a group of 27 patients with histologically proven metastatic renal-cell carcinoma who participated in a phase II study of treatment with subcutaneous rIl-2 (Sleijfer et al., 1992) (Sleijfer et al., 1990) . Patients were grouped as follows: patients 1-4 had progressive disease, patients 5-8 showed stable disease and patients 9-12 had complete or partial remission. A full report describing the clinical findings in these patients have been published elsewhere (Sleijfer et al., 1992) .
Blood samples were obtained before and during treatment three times a week. Within 1 h after obtaining the EDTA blood sample (on ice) plasma was removed and frozen at -20°C until assayed.
Assays
The levels of soluble interleukin-2 receptor and soluble CD8 molecules were measured in plasma by sandwich enzyme immunoassays with use of reagents and directions supplied by the manufacturer (T Cell Sciences, Inc, Cambridge, Massachusetts). In short, both tests employ two noncompeting monoclonal antibodies, one catching and one indicator (horseradish peroxidase conjugated). Coated plastic microwells were incubated with sample, washed and indicator antibody was added. After washing the reaction mixture (OPD) was added and the absorbance was measured.
The assays are calibrated on manufacturers' reference preparations of culture supernatants. The intra-assay precision of the sIl-2R assay has a coefficient of variation between 2-5%, the sCD8 assay between 4-8% (inter-assay coefficient of variation: sIl-2R ± 5%, sCD8 ± 10%).
Both tests do not detect any known cross-reactive antigens and no interference with haemoglobin, bilirubin, protein and lipids have been shown. The detection limit for both tests is ± 50 U ml-'.
Results sigmtfcantly hil parison with ti
The sIl-2R plasma levels of renal cell carcinoma patients (P<0.01, Wil before and during sc-rIl-2 therapy are given in Table I . All patients show a marked increase of the plasma sIl-2R concentration during therapy as compared to pretreatment Figure 1 Changes in sIl-2R concentration during therapy in a representative patient. 
Discussion
Although sera from the aged compared to young adults contain higher levels of sIl-2R (65-82 years old: 604 ± 412 U ml-') (Saadeh et al.,1986) patients with metastatic renal carcinoma prove to have relatively high base levels of soluble 11-2 receptor in the blood (mean RCC patients: 1074 ± 624 U ml-', see Table I ). Other studies (Lissoni et al., 1990 ) also indicated increased sIl-2R concentration in patients with solid tumours like breast cancer, small cell and non-small cell lung cancer, colorectal cancer, gastric cancer and cervix carcinoma. It is unclear if these relatively high base levels reflect an ongoing baseline activation of the immune system in these patients. However, there seems no indication of an activation of the effector phase of the immune response before therapy as reflected by plasma sCD8 levels which were comparable to (except the dialysis patients) the ones found in healthy persons (138-533 U ml-').
During the subcutaneous administration of recombinant interleukin-2 there was a strong rise of the sIl-2R plasma concentration in all patients. In the first week of treatment most patients did reach high levels (mean: 17.2 x baseline level) of sI1-2R which remained high during the whole 6 week treatment period (example: Figure 1) . About the same increase was seen in other studies (Lotze et al., 1987) where interleukin-2 was administered i.v. (continuously as well as intermittently). These results suggest that despite the subcutaneous administration which did reduce toxicity dramatically the immunological changes are as significant as during the i.v. therapy.
Although the plasma sIl-2R concentration can be used as an indicator of the proliferative phase of the immune response a possible function of this soluble receptor molecule remains obscure. It has been suggested that sI1-2R causes a down-regulation of the immune response by for example binding free 11-2 (Rubin et al., 1985) . Other suggestions however, that it may act as a chaperone for 11-2 seem to be possible although the sIl-2R/II-2 complex has a molecular weight of a mere 60-65 kD which is quite small for such a function. a
During therapy we noted also an increase of the sCD8 plasma concentration. However, this rise was not as strongly marked as the sII-2R increase and did not last during the whole therapy cycle (see Figure 2) . Most patients had a peak concentration in the second week of treatment after which the level returned to the baseline. Since the base sCD8 concentration varied between patients before treatment we calculated the sCD8 ratio ([sCD8] peak value/[sCD8] before therapy) so that each patient served as its own control.
Interestingly the patients with a partial or complete remission showed a significantly higher relative increase of the sCD8 concentration in comparison with patients with stable or progressive disease (Figure 3) . These results indicate a correlation between the relative sCD8 concentration increase and the patients response rate.
High soluble CD8 levels appear to originate from interaction of CD8 + effector cells with target cells (Fujimoto et al., 1984) . It is still not clear which cells during therapy are the main source of the sCD8 production; the CD8 + T-cells or the CD8 + NK-cells. The reason why sCD8 concentration decreases again during the second half of therapy is unclear since there seems to be a continued high status of activation of the proliferative phase of the immune response as reflected by the high plasma sI1-2R levels. These results may suggest that during prolonged rIl-2 therapy (CD8 +) cytotoxic T cells may become suppressed. So it may be possible that continuing rIl-2 therapy after ± 3 weeks is less effective because of the development of immune suppression.
In conclusion: during subcutaneous interleukin-2 therapy of renal carcinoma there is a strongly marked activation of the proliferative phase of the immune response reflected by the strong plasma sIl-2R increasement. sCD8 is increased only to a moderate extent. Importantly however, the sCD8 results show a correlation between the sCD8 plasma concentration and the patients' response rate. During rIl-2 therapy a form of immunosuppression involving CD8 + cells may develop as is reflected by a lower sCD8 concentration in the second half of therapy. 
